End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
15.98 CNY | -2.86% | -4.65% | -10.73% |
30/04 | Mainland China stocks edge lower ahead of long Labor Day holiday, Hong Kong rises | RE |
26/04 | Cabio Biotech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 59% by 2026.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
Weaknesses
- The company is not the most generous with respect to shareholders' compensation.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Food Processing
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-10.73% | 37Cr | - | ||
+15.09% | 828.41Cr | D+ | ||
+3.37% | 770.73Cr | C- | ||
+1.45% | 600.47Cr | - | ||
-6.26% | 371.16Cr | B- | ||
-9.86% | 360.5Cr | D | ||
-6.55% | 128.52Cr | - | - | |
-28.83% | 108.56Cr | B+ | ||
+14.31% | 99Cr | - | ||
-10.78% | 91Cr | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
- Stock Market
- Equities
- 688089 Stock
- Ratings Cabio Biotech (Wuhan) Co., Ltd.